Guggenheim Capital LLC Has $736,000 Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Guggenheim Capital LLC grew its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 141.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,078 shares of the company’s stock after purchasing an additional 11,180 shares during the quarter. Guggenheim Capital LLC’s holdings in Protagonist Therapeutics were worth $736,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of PTGX. FNY Investment Advisers LLC purchased a new stake in shares of Protagonist Therapeutics in the fourth quarter valued at about $38,000. Covestor Ltd grew its holdings in shares of Protagonist Therapeutics by 5,200.0% in the fourth quarter. Covestor Ltd now owns 1,643 shares of the company’s stock valued at $63,000 after acquiring an additional 1,612 shares in the last quarter. KBC Group NV lifted its holdings in Protagonist Therapeutics by 54.4% during the fourth quarter. KBC Group NV now owns 2,093 shares of the company’s stock worth $81,000 after acquiring an additional 737 shares during the period. Nisa Investment Advisors LLC boosted its position in Protagonist Therapeutics by 10.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock worth $121,000 after purchasing an additional 295 shares during the last quarter. Finally, Cibc World Markets Corp purchased a new stake in shares of Protagonist Therapeutics during the 4th quarter valued at $211,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Insider Activity at Protagonist Therapeutics

In related news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $38.18, for a total value of $204,606.62. Following the sale, the chief executive officer now directly owns 540,260 shares of the company’s stock, valued at $20,627,126.80. This trade represents a 0.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Arturo Md Molina sold 30,514 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the completion of the transaction, the insider now directly owns 83,892 shares of the company’s stock, valued at approximately $4,676,140.08. This represents a 26.67 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 66,532 shares of company stock valued at $3,665,786. Company insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Trading Down 2.8 %

Shares of Protagonist Therapeutics stock opened at $44.85 on Friday. The company’s 50-day moving average price is $45.45 and its 200-day moving average price is $42.85. Protagonist Therapeutics, Inc. has a 12-month low of $24.22 and a 12-month high of $60.60. The company has a market cap of $2.75 billion, a price-to-earnings ratio of 16.86 and a beta of 2.30.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $2.07. The business had revenue of $170.64 million for the quarter, compared to analysts’ expectations of $56.65 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. On average, sell-side analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. BMO Capital Markets increased their price target on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Protagonist Therapeutics in a research note on Thursday, April 10th. JMP Securities reiterated a “market outperform” rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, February 7th. BTIG Research set a $73.00 target price on Protagonist Therapeutics in a research report on Monday, March 3rd. Finally, Truist Financial increased their price target on Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a “buy” rating in a research note on Tuesday, March 11th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $65.44.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.